Lexicon Pharmaceuticals Inc (LXRX) FinancialsLXRXLexicon Pharmaceuticals Inc

Evaluating the bottom line, Lexicon Pharmaceuticals, Inc. maintains a gross margin of 94.36%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -3835.26%, while the net margin is -4591.76%. These profitability ratios, combined with a Return on Equity (ROE) of -40.21%, provide a clear picture of how effectively LXRX converts its operational activities into shareholder value.

In the context of the broader market, LXRX competes directly with industry leaders such as GYRE and SLBT. With a market capitalization of $747.53M, it holds a leading position in the sector. When comparing efficiency, LXRX's gross margin of 94.36% stands against GYRE's 92.41% and SLBT's N/A. Such benchmarking helps identify whether Lexicon Pharmaceuticals, Inc. is trading at a premium or discount relative to its financial performance.

Lexicon Pharmaceuticals has shown fluctuating revenue, with a total revenue of 26554000 USD in Q4 2024, but it reported a significant net loss of -31775000 USD in Q2 2026. The gross margin remains high at 94.36% in Q2 2026, but the company has not been profitable recently, as indicated by the negative net income figures.